

**COMPENSATION RESULTS BY NIOSH-IREP CANCER MODEL
BASED ON CLAIMS WITH DR APPROVED AND SUBMITTED TO DOL THROUGH SEP. 23, 2015 (37,155 CLAIMS)**

Rank by Compensation Rate	NIOSH-IREP CANCER MODEL (ICD-9 Code)	Compensated (PC ≥ 50%)		Not Compensated (PC < 50%)		Total Claims	
		Claims with a Single Primary Cancer	N	%	N	%	N
1	Lung (162)	3167	63.7	1801	36.3	4968	19.3
2	Chronic Myeloid Leukemia (205.1)	54	53.5	47	46.5	101	0.4
3	Non-melanoma skin-Basal Cell (173)	1143	52.5	1033	47.5	2176	8.5
4	Acute Lymphocytic Leukemia (204.0)	41	47.1	46	52.9	87	0.3
5	Liver (155.0)	89	41.0	128	59.0	217	0.8
6	Lymphoma & multiple myeloma (200-203)	733	38.2	1186	61.8	1919	7.5
7	Acute Myeloid Leukemia (205.0)	76	35.0	141	65.0	217	0.8
8	Malignant melanoma (172)	260	34.1	503	65.9	763	3.0
9	Leukemia, excl. CLL (204-208, excl. 204.1)	45	30.8	101	69.2	146	0.6
10	Other respiratory (160,161,163-165)	207	30.0	482	70.0	689	2.7
11	Chronic Lymphocytic Leukemia (204.1)	72	29.8	170	70.2	242	0.9
12	Oral Cavity and Pharynx (140-149)	104	20.8	397	79.2	501	1.9
13	Bone (170)	42	16.6	211	83.4	253	1.0
14	Thyroid (193)	59	15.6	320	84.4	379	1.5
15	Gallbladder (155.1,156)	18	14.4	107	85.6	125	0.5
16	Stomach (151)	56	9.4	541	90.6	597	2.3
17	Eye (190)	5	8.1	57	91.9	62	0.2
18	Colon (153)	103	7.7	1231	92.3	1334	5.2
19	Bladder (188)	48	7.0	640	93.0	688	2.7
20	Urinary organs, excluding bladder (189)	43	6.2	648	93.8	691	2.7
21	All Male Genitalia (185-187)	165	3.3	4810	96.7	4975	19.3
22	Other endocrine glands (194)	1	3.2	30	96.8	31	0.1
23	All digestive (150-159)	4	3.2	121	96.8	125	0.5
24	Esophagus (150)	4	2.4	161	97.6	165	0.6
25	Connective tissue (171)	4	2.3	168	97.7	172	0.7
26	Non-melanoma skin-Squamous Cell (173)	15	1.9	784	98.1	799	3.1
27	Other and ill-defined sites (195)	1	1.6	61	98.4	62	0.2
28	Breast (174-175)	17	1.5	1103	98.5	1120	4.4
29	Pancreas (157)	9	1.4	652	98.6	661	2.6
30	Rectum (154)	5	0.9	562	99.1	567	2.2
31	Nervous system (191-192)	2	0.4	459	99.6	461	1.8
32	Female Genitalia, excl. ovary (179-182,184)	0	0.0	313	100.0	313	1.2
33	Ovary (183)	0	0.0	135	100.0	135	0.5
Subtotal for Claims with a Single Primary Cancer		6592	25.6	19149	74.4	25741	69.3
Subtotal for Claims with 2 Primary Cancers		1756	29.1	4287	70.9	6043	16.3
Subtotal for Claims with 3 Primary Cancers		855	39.1	1333	60.9	2188	5.9
Subtotal for Claims with 4 or more Primary Cancers		1276	40.1	1907	59.9	3183	8.6
Subtotal for Claims with Multiple Primary Cancers		3887	34.1	7527	65.9	11414	30.7
GRAND TOTAL (ALL CLAIMS)		10479	28.2	26676	71.8	37155	100.0



The data presented on this page:
 May not be predictive of future results;
 Reflect claims with only one reported primary cancer (unless otherwise noted); and,
 Are in some cases based on a small number of cases.



The data present on this page are indicative of compensation rates for claims that have gone through dose reconstruction and do not include claims that have been awarded compensation through the Special Exposure Cohort (SEC) process. Thus, overall compensation rates for the 22 cancers that are included in the SEC may be higher.